Home > Market > Market Stats >  Indoco Remedies

Indoco Remedies

Sector: Biotechnology & Drugs
Powered by
330.00 +8.45 (2.63%)
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y

Price Range

Today’s Low 318.35
Today’s High 331.15
52 Week Low 307.95
52 Week High 511.94

Key Metrics

  • Market Cap (In Cr) 2964.02
  • Beta 0.74
  • Div. Yield (%) 0.47
  • P/B 3.28
  • TTM P/E 21.96
  • Peg Ratio 0.67
  • Sector P/E 24.66
  • D/E -
  • Open Price 321.55
  • Prev Close 321.55
View All Metrics on Mint Genie

Analysis

Price Analysis
  • 1 Week
    -5.98%
  • 3 Months
    -12.19%
  • 6 Month
    -14.52%
  • YTD
    -29.05%
  • 1 Year
    -27.51%
Risk Meter
  • 30% Low risk
  • 30% Moderate risk
  • 30% Balanced Risk
  • 30% High risk
  • 30% Extreme risk
Recos
7 Analysts
  • Strong Sell
  • Sell
  • Hold
  • Buy
  • Strong Buy
Analysts' Views
  • Ratings
  • Current
  • Strong Sell
  • 0
  • Sell
  • 0
  • Hold
  • 1
  • Buy
  • 2
  • Strong Buy
  • 4

Financials

  • INCOME
  • BALANCE SHEET
  • Cashflow
  • Period
  • 2022
  • Total Revenue
  • 1540.75
  • Selling/ General/ Admin Expenses Total
  • 582.36
  • Depreciation/ Amortization
  • 77.21
  • Other Operating Expenses Total
  • 33.5
  • Total Operating Expense
  • 1291.84
  • Operating Income
  • 248.92
  • Net Income Before Taxes
  • 236.57
  • Net Income
  • 154.8
  • Diluted Normalized EPS
  • 16.96
  • Period
  • 2021
  • Total Revenue
  • 1241.53
  • Selling/ General/ Admin Expenses Total
  • 514.68
  • Depreciation/ Amortization
  • 73.13
  • Other Operating Expenses Total
  • 35.59
  • Total Operating Expense
  • 1090.12
  • Operating Income
  • 151.41
  • Net Income Before Taxes
  • 132
  • Net Income
  • 93.05
  • Diluted Normalized EPS
  • 10.12
  • Period
  • 2020
  • Total Revenue
  • 1106.58
  • Selling/ General/ Admin Expenses Total
  • 530.34
  • Depreciation/ Amortization
  • 67.95
  • Other Operating Expenses Total
  • 23.01
  • Total Operating Expense
  • 1053.94
  • Operating Income
  • 52.64
  • Net Income Before Taxes
  • 28.57
  • Net Income
  • 24.12
  • Diluted Normalized EPS
  • 2.9
  • Period
  • 2019
  • Total Revenue
  • 968.45
  • Selling/ General/ Admin Expenses Total
  • 454.54
  • Depreciation/ Amortization
  • 71.57
  • Other Operating Expenses Total
  • 23.72
  • Total Operating Expense
  • 963.16
  • Operating Income
  • 5.29
  • Net Income Before Taxes
  • -9.31
  • Net Income
  • -2.9
  • Diluted Normalized EPS
  • -0.28
  • Period
  • 2018
  • Total Revenue
  • 1045.3
  • Selling/ General/ Admin Expenses Total
  • 444.58
  • Depreciation/ Amortization
  • 67.71
  • Other Operating Expenses Total
  • 21.18
  • Total Operating Expense
  • 977.91
  • Operating Income
  • 67.38
  • Net Income Before Taxes
  • 48.4
  • Net Income
  • 41.16
  • Diluted Normalized EPS
  • 4.32
  • Period
  • 2017
  • Total Revenue
  • 1096.77
  • Selling/ General/ Admin Expenses Total
  • 444.68
  • Depreciation/ Amortization
  • 63.28
  • Other Operating Expenses Total
  • 26.08
  • Total Operating Expense
  • 1003.26
  • Operating Income
  • 93.51
  • Net Income Before Taxes
  • 90.94
  • Net Income
  • 77.06
  • Diluted Normalized EPS
  • 8.38
View detailed financials on Mint Genie

Forecast

Income Sheet (In Cr) Net Income Vs Revenue
Returns Metrics (In Cr) ROA Vs ROE

Technical

Moving Average SMA
  • 5 Day329.83
  • 10 Day341.14
  • 20 Day352.97
  • 50 Day365.89
  • 100 Day364.51
  • 300 Day381.34

Peers

  • Price
  • Ratio
  • Name
  • Latest Price
  • Change
  • % Change
  • 52W High
  • 52W Low
  • Mkt. Cap

Corporate Actions

  • Board Meeting
  • AGM
  • Dividends
  • Bonus
  • Split
  • Rights
  • Meeting Date
  • Purpose
  • 09-Aug-22
  • Quarterly Results
  • 17-May-22
  • Audited Results & Final Dividend
  • 01-Feb-22
  • Quarterly Results
  • 02-Nov-21
  • Quarterly Results
  • 11-Aug-21
  • Quarterly Results
  • 25-May-21
  • Audited Results & Final Dividend
  • 09-Feb-21
  • Quarterly Results

Company Profile

ABOUT Indoco Remedies

  • Industry Biotechnology & Drugs
  • ISIN INE873D01024
  • BSE Code 532612
  • NSE Code INDOCO

Indoco Remedies Limited is an India-based company, which is engaged in the manufacture of pharmaceutical products. The Company is an integrated, research-oriented pharma company engaged in the manufacturing and marketing of formulations (finished dosage forms) and active pharmaceutical ingredients (APIs). The Company's geographical segments include India and Outside India. The Company has nine domestic marketing divisions with a brand portfolio in various therapeutic segments, including Gastrointestinal, Respiratory, Anti-Infective, Stomatologicals, Ophthalmic, Nutritionals, Cardiovascular, Anti-Diabetics, Pain Management and Gyneacology. The Company’s brands include Cyclopam, Febrex Plus, Sensodent-K, Karvol Plus, ATM, Oxipod, Cital, Sensoform, Sensodent-KF, Cal-Aid, Cloben-G, Glychek, Kidodent, Carmicide, Rexidin, MCBM and Methycal.

MANAGEMENT

  • Suresh Kare Executive Chairman of the Board
  • Aditi Panandikar Chief Executive Officer, Managing Director, Executive Director
  • Pramod Ghorpade Chief Financial Officer
  • Jayshankar Menon Assistant Vice President - Legal, Compliance Officer, Company Secretary
  • Sundeep Bambolkar Joint Managing Director, Executive Director

Company Summary

INDOCO REMEDIES SUMMARY

Indoco Remedies is trading 2.63% upper at Rs 330.00 as compared to its last closing price. Indoco Remedies has been trading in the price range of 331.15 & 318.35. Indoco Remedies has given -29.05% in this year & -5.98% in the last 5 days.

 

Indoco Remedies has TTM P/E ratio 21.96 as compared to the sector P/E of 24.66. There are 7 analysts who have initiated coverage on Indoco Remedies. There are 4 analysts who have given it a strong buy rating & 2 analysts have given it a buy rating. 0 analysts have given the stock a sell rating.

 

The company posted a net profit of 38.57 Crores in its last quarter.

 

Listed peers of Indoco Remedies include Shilpa Medicare (6.46%), Advanced Enzyme Technologies (-0.83%), Indoco Remedies (2.63%) etc.

FAQs about Indoco Remedies

Indoco Remedies is trading at 330.00 as on 30 Sep, 2022 3:29:50 PM. This is 2.63% upper as compared to its previous closing price of 321.55
The market capitalization of Indoco Remedies is 2964.02 Cr as on 30 Sep, 2022 3:29:50 PM.
The average broker rating on Indoco Remedies is Strong Buy. The breakup of analyst rating is given below -
  • 0 analysts have given a strong sell rating
  • 0 analysts have given a sell rating
  • 1 analysts have given a hold rating
  • 2 analysts have given a buy rating
  • 4 analysts have given a strong buy rating
The 52 wk high for Indoco Remedies is 511.94 whereas the 52 wk low is 307.95
Indoco Remedies can be analyzed on the following key metrics -
  • TTM P/E: 21.96
  • Sector P/E: 24.66
  • Dividend Yield: 0.47%
  • D/E ratio: -
Indoco Remedies reported a net profit of 154.8 Cr in 2022.

Recommended For You

Trending Stocks

×
Get alerts on WhatsApp
Set Preferences My ReadsWatchlistFeedbackRedeem a Gift CardLogout